The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This is expected to drive a substantial increase in the number of trials seeking to enroll children. Parents and caregivers are likely to have many questions when considering whether to enroll a child in a clinical trial, and children, perhaps particularly adolescents, will also have their own lists of questions, so adequate time must be allowed for these questions to be asked and answered.
Global Pediatric Drug Development Collaboration Part One
The pharmaceutical industry is unlike any other industry in that the products manufactured can dramatically improve, and even save, lives. This is…
How do we safely send kids to school during a pandemic?
The COVID-19 pandemic has led to the nationwide closure of schools and universities in more than 190 countries, impacting 1.57 billion students.
Ask the Experts: How is the Medical Industry Currently Addressing Sickle Cell Disease?
Sickle Cell Disease (SCD) is a disease with few curative treatments that affects people globally. Both young and older patients who struggle with SCD…